The idea of personalized cancer medicine has stayed at the concept stage until recently. With the exciting progress on deep sequencing technology, personalized medicine receives more and more attention. To embrace this new exciting trend, the Elsevier conference: 2015 Miami winter symposium, entitled "Towards the Personalized Cancer Medicine" convened from January 18 th through January 21 st , 2015 at Miami, FL.
The four-day scientific content covered basic cancer research and a variety of novel or emerging therapeutic approaches. The meeting consisted of six scientific sessions that included plenary talks given by twenty-five top-level leaders as well as three young investigators from both academia and industry. The subject material was diverse and included cancer heterogeneity, genetics, epigenetics, molecular mechanisms, targeted therapies, immune therapies and translational/clinical research. Exciting progress was reported on designing next-generation targeted therapy drugs, including inhibitors for BRD4, proteasome, deubiquitylase, and histone deacetylase. Perhaps the best feature of the meeting was the young investigator talks on the third day, in which trainees gave compelling fifteen-minute talks. Dr. Xiaoxia Zhu from the University of Miami presented a computational biochemical approach to investigate novel inhibitors of notch signaling pathway. Drs. Azzam and Bhang talked about drug screening in ovarian cancer and lentivirusmediated cell barcoding technique to study cancer cell clonal dynamics, respectively.
Finally, in addition to the continuous success in chemical drugs, designing antibody drugs to inhibit tumor growth and to restore immunity was another hot topic in the meeting. Albeit tumor escaping immune surveillance by inhibiting immune checkpoint pathway has been known for years, and targeting this pathway to treat cancer has stagnated in clinic. One checkpoint protein is PD-1, which recruits a phosphatase and may interfere with T cell antigen receptor mediated signaling. Dendritic cells express PD-1 ligases, PD-L1 and PD-L2. Many tumor cells also express PD-L1, and its subsequent interaction with PD-1 on T cells is demonstrated to be a major mechanism of losing T cell immunity. Many pharmaceutics have developed PD-1 and PD-L1 antibodies, such as pembrolizumab (Merck), MPDL3280A (Genentech/ Roche), nivolumab (Bristol-Myers Squibb) and MEDI4736 (Medimmune). These antibody drugs have shown responses against cancers of the lung, kidney, skin, bladder, head and necks. Some lymphomas showed response rates of 25% to 30% in clinical trials. Notably, FDA approved recently pembrolizumab for
